Research on safety and effect of lipid improvement of rosuvastatin combined with fenofibrate or EPA in type 2 diabetic patients with hyperlipidemia
Phase of Trial: Phase IV
Latest Information Update: 09 May 2017
At a glance
- Drugs Rosuvastatin (Primary) ; Eicosapentaenoic acid; Fenofibrate
- Indications Hyperlipidaemia
- Focus Therapeutic Use
- 07 Dec 2012 Planned End Date changed to 1 Sep 2010 as reported by University Hospital Medical Information Network - Japan record.